Close

Athersys (ATHX) MultiStem Phase 2 Missed Primary, Secondary Endpoints

April 17, 2015 6:02 AM EDT Send to a Friend
Athersys (NASDAQ: ATHX) announced interim results from its exploratory Phase 2 clinical study of the intravenous administration of MultiStem cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login